skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Clinical applications of azithromycin microspheres in respiratory tract infections

(2881) Views  (706) Full article downloads

Authors: Francesco Blasi, Stefano Aliberti, Paolo Tarsia

Published Date January 2007 Volume 2007:2(4) Pages 551 - 559
DOI: http://dx.doi.org/10.2147/IJN.S

Francesco Blasi, Stefano Aliberti, Paolo Tarsia

Institute of Respiratory Diseases, University of Milan, IRCCS Fondazione Policlinico-Mangiagalli-Regina Elena Milano, Italy

Abstract: Few adequately designed clinical trials have addressed optimal treatment duration in lower respiratory tract infections. Drugs possessing favourable pharmacokinetic and pharmacodynamic profiles may obtain early bacterial eradication allowing shorter treatment duration. This may be associated with a number of advantages including reduced resistance induction, increased compliance, lesser adverse events, and cost containment. Recently, a novel 2.0 g single dose of azithromycin microspheres has been compared with 7-day levofloxacin 500 mg or extended release clarithromycin in over 400 patients with community-acquired pneumonia. Clinical cure and bacteriological eradication rates, hospitalizations, and deaths were similar between azithromycin and comparators. Azithromycin 2.0 g microspheres proved as effective as 7 days of levofloxacin 500 mg in acute exacerbation of chronic bronchitis patients across all degrees of obstruction severity. In both settings Azithromycin microspheres obtained clinical cure in most patients harbouring macrolide-resistant Streptococcus pneumoniae strains. The drug was well tolerated in clinical studies and in healthy volunteers with modest and transitory adverse events. An undoubted advantage of single-dose azithromycin administration is the facility in ensuring that patients complete their prescribed course of therapy. A further advantage of single-dose therapy is the potential for use as directly-observed therapy, which may be useful in specific clinical conditions.

Keywords: azithromycin microspheres, pneumonia, COPD exacerbations








Readers of this article also read:

Single-dose azithromycin microsphere formulation: a novel delivery system for antibiotics
Adverse effects of fullerenes on endothelial cells: Fullerenol C60(OH)24 induced tissue factor and ICAM-1 membrane expression and apoptosis in vitro
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Amino acid-responsive Crohn's disease: a case study
Amino acid management of Parkinson’s disease: a case study
Formulation and evaluation of Bacillus coagulans-loaded hypromellose mucoadhesive microspheres
Suitable carriers for encapsulation and distribution of endostar: comparison of endostar-loaded particulate carriers
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines